Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00348491 · ClinicalTrials.gov registry record · Phase 4
Efficacy of Lumiracoxib in Relieving Moderate to Severe Post-dental Surgery Pain, Compared to Both Placebo and Celecoxib
A Phase 4 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 364
- Enrollment target
NCT00348491 is a Phase 4 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 364 participants.
The verdict
NCT00348491, a Phase 4 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 364 participants
- Enrollment target
Study Summary
This study will assess the safety and efficacy of lumiracoxib 400 mg in relieving moderate to severe post-dental surgery pain, compared to both placebo and celecoxib 400 mg.
Interventions
- DRUG Lumiracoxib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 364 participants |
| Start Date | 2006-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00348491
The ClinicalTrials.gov registry entry for NCT00348491 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 364 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lumiracoxib is the first listed.
NCT00348491 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00348491 about?
NCT00348491 is a clinical study titled "Efficacy of Lumiracoxib in Relieving Moderate to Severe Post-dental Surgery Pain, Compared to Both Placebo and Celecoxib". This study will assess the safety and efficacy of lumiracoxib 400 mg in relieving moderate to severe post-dental surgery pain, compared to both placebo and celecoxib 400 mg.
What is the current status of trial NCT00348491?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 364 participants. The study started on 2006-02.
What interventions are being tested in trial NCT00348491?
The interventions under investigation include: Lumiracoxib (DRUG).
Who is sponsoring clinical trial NCT00348491?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.